Patents Assigned to Everest Biosciences, Inc.
  • Patent number: 9066947
    Abstract: The disclosure describes compounds of formula I, wherein the wedged bonds, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, X and Y have meanings given in the description, and pharmaceutically-acceptable salts thereof; and methods of using such compounds useful in the treatment of cancer and conditions affected by inhibition of angiogenesis. Also provided, are processes for the preparation of formula I, by reacting formula I with other compounds; and processes for the preparation of a pharmaceutical formulation by bringing into association, a compound of formula I, with therapeutic agents and/or a pharmaceutically-acceptable adjuvant, diluent, or carrier.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: June 30, 2015
    Assignee: EVEREST BIOSCIENCES, INC.
    Inventors: Jenny Persson, Rikard Larsson, Olov Sterner, Martin Johansson
  • Publication number: 20140235644
    Abstract: The disclosure describes compounds of formula I, wherein the wedged bonds, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, X and Y have meanings given in the description, and pharmaceutically-acceptable salts thereof; and methods of using such compounds useful in the treatment of cancer and conditions affected by inhibition of angiogenesis. Also provided, are processes for the preparation of formula I, by reacting formula I with other compounds; and processes for the preparation of a pharmaceutical formulation by bringing into association, a compound of formula I, with therapeutic agents and/or a pharmaceutically-acceptable adjuvant, diluent, or carrier.
    Type: Application
    Filed: April 28, 2014
    Publication date: August 21, 2014
    Applicant: Everest Biosciences, Inc.
    Inventors: Jenny Persson, Rikard Larsson, Olov Sterner, Martin Johansson
  • Patent number: 8754086
    Abstract: The disclosure describes compounds of formula I, wherein the wedged bonds, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, X and Y have meanings given in the description, and pharmaceutically-acceptable salts thereof; and methods of using such compounds useful in the treatment of cancer and conditions affected by inhibition of angiogenesis. Also provided, are processes for the preparation of formula I, by reacting formula I with other compounds; and processes for the preparation of a pharmaceutical formulation by bringing into association, a compound of formula I, with therapeutic agents and/or a pharmaceutically-acceptable adjuvant, diluent, or carrier.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: June 17, 2014
    Assignee: Everest Biosciences, Inc.
    Inventors: Jenny Persson, Rikard Larsson, Olov Sterner, Martin Johansson